Bruker Unveils New proteoElute™ nanoLC System and PepSep® Advanced nLC Columns for up to 50% Improved Peptide Sensitivity
A. Bruker Introduces the proteoElute Next-Generation Nanoflow LC System for Robust, Ultra-Sensitive Proteomics Workflows with Real-time Monitoring
Bruker announces the launch of the proteoElute, a state-of-the-art nanoflow liquid chromatography (LC) system designed for robust and ultra-sensitive multiomics applications. The proteoElute is ideal for single-cell proteomics, immunopeptidomics, microbiome metaproteomics profiling, and many other proteomics methods, ensuring reliable performance even with limited or very complex biological samples.
The proteoElute features innovative TwinScape™ technology, which continuously monitors system health in real-time and runs background diagnostics. This proactive approach alerts users to potential issues, providing peace of mind when working with precious samples.
Engineered for relentless reliability, the proteoElute includes biocompatible ceramic valves, new porous metal filters, and a proprietary trap column that together enhance robustness, chromatographic performance, and permit sample recovery. The new injector and needle wash system reduces carry-over by up to 3x, a critical advantage for confidently avoiding background signals when analyzing ultra-low input samples.
W. Hayes McDonald, Associate Director in the Department of Biochemistry at Vanderbilt University, commented: ' The combination of the new proteoElute UHPLC platform along with updated PepSep Advanced columns and the proteoTrap column allows us the flexibility to perform any state-of-the-art proteomics workflow with highest performance. Its remarkable robustness gives us the confidence to execute all proteomics workflows at scale. '
B. Bruker Introduces PepSep Advanced Columns for Sharper nLC Peaks, Higher Sensitivity and Further Enhanced Peptide and Protein Identifications
For highest sensitivity and performance of the proteoElute nLC system, Bruker introduces a new generation of PepSep Advanced nLC columns, engineered for precision, robustness, and speed. The columns deliver sharper peaks and higher-resolution separations for even deeper proteome coverage and consistent performance with challenging biological samples. In benchmark studies, the PepSep Advanced columns demonstrated approximately 20% improvements in peptide IDs and typically 10% improvements in protein IDs.
Combined with CaptiveSpray Ionization (CSI) emitters, users can extend column lifetime by simply replacing the emitter—ensuring long-term performance and cost efficiency. PepSep columns provide the reliability and depth needed for analyzing complex tissue digests or low-input samples.
Lynn Spruce, the Technical Director at the Children's Hospital of Philadelphia (CHOP-Penn) Proteomic Core Facility, said: 'The new PepSep Advanced columns have proven to be robust, and they consistently deliver reproducible chromatography. They produce sharper, more symmetrical peaks with no observable tailing, resulting typically in 7–8% increases in protein group identifications. Combined with the convenience of interchangeable emitters and reasonable pricing, it has become our go-to nLC column. It's essentially plug-and-play.'
About Bruker Corporation – Leader of the Post-Genomic Era (Nasdaq: BRKR)
Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker's high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in post-genomic life science molecular and cell biology research, in applied and biopharma applications, in microscopy and nanoanalysis, as well as in industrial and cleantech research, and next-gen semiconductor metrology in support of AI. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit www.bruker.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 minutes ago
- Yahoo
Intel stock falls after Trump administration reportedly considers 10% stake
-- Intel (NASDAQ:INTC) stock declined 5% following a Bloomberg report that the Trump administration is discussing taking a stake of approximately 10% in the chipmaker. According to the report, the federal government is considering converting some or all of Intel's $10.9 billion in Chips and Science Act grants into equity. At Intel's current market valuation, a 10% stake would be worth roughly $10.5 billion. The exact size of the potential stake and whether the administration will proceed with the plan remain undetermined, according to people familiar with the matter who requested anonymity. The White House has not confirmed specific details. The report also suggested the administration might consider converting other Chips Act awards into equity stakes, though it's unclear if this approach has gained broader support within the government or if officials have discussed it with other potential companies. News of the potential government investment initially sparked a rally in Intel shares last week, with the stock rising 23% for its best weekly gain since February. However, investors appeared to reassess the implications on Monday, sending shares lower. Related articles Intel stock falls after Trump administration reportedly considers 10% stake Victoria's Secret Exposed: The Warning Sign Behind the Stock's 52% Collapse Tesla: Hype Aside, How Much Is the EV Giant Really Worth Now?
Business Wire
32 minutes ago
- Business Wire
Sammons Financial Group Employees Direct $175,000 to Iowa Charities
WEST DES MOINES, Iowa--(BUSINESS WIRE)-- Sammons ® Financial Group, Inc. announced the results of its 2025 Community Outreach Program. Sammons Financial Group employees selected 25 organizations to receive a total of $175,000 in financial support. Recipient charities were invited to the company's West Des Moines headquarters to further connect with employees about their organization and mission. The initiative, started in 2018, empowers employees to nominate their favorite local charities to be considered for a financial grant from Sammons Financial Group. The employees who choose to make nominations are given the opportunity to educate their coworkers on the mission of the organization and why they are passionate about it. Employees then vote for the organizations they would like the company to support financially. 'Our employees selected this year's recipients because of the excellent work they do in our community,' said Casey Decker, West Des Moines site leader and Chief Operating Officer at Sammons Financial Group. 'We're proud to support these organizations elevating the quality of life in Central Iowa.' The following organizations received funding from the 2025 Community Outreach Program: Aheinz57 American Cancer Society (Iowa Chapter) American Lung Association of Iowa American Parkinson Association Iowa Chapter Animal Rescue League of Iowa Building Brave Teams Camp Fire of Iowa Combat Vets Motorcycle Association Iowa Chapter 39-1 Des Moines Refugee Support Focuss Four Oaks Foster and Adoption Support Great Plains Pointer Rescue Hope Ministries Iowa Donor's Network Iowa Jobs for America's Graduates Kid Hope USA Leukemia and Lymphoma Society of Iowa Mason's Lighthouse Peace Creek Animal Sanctuary and Rescue SEEDS Shriner's Children's Hospital in partnership with Blank Children's Hospital Sleep in Heavenly Peace The Supply Hive Urban Bicycle Food Ministry Waypoint Resources The Community Outreach Program is one part of Sammons Financial Group's longstanding commitment to its communities. In 2024, the company donated $4.7 million to local charities through its various charitable giving programs. West Des Moines is home to about 1,000 on-site and remote employees. A similar program is held each year in the Sioux Falls office, which has 600 employees. About Sammons ® Financial Group, Inc. Sammons Financial Group ® helps families and businesses by empowering futures and changing lives. Sammons Financial Group is employee owned with member companies that are among the most enduring and stable in the financial services industry. Our member companies include Midland National ® Life Insurance Company (including Sammons ® Corporate Markets); North American Company for Life and Health Insurance ®; Sammons Institutional Group ® (including Midland Retirement Distributors ® and Sammons Retirement Solutions ®) and Sammons Wealth Management Group. Committed to our communities, Sammons Financial Group is Midwest-based, with offices in Iowa, Illinois, Minnesota, North Dakota, Ohio, and South Dakota.
Business Wire
32 minutes ago
- Business Wire
Accenture Acquires The Highlands Consulting Group
NEW YORK & SACRAMENTO, Calif.--(BUSINESS WIRE)--Accenture (NYSE: ACN) has acquired The Highlands Consulting Group, a leading management consulting provider with extensive experience in healthcare, transportation, social services and environmental solutions. This move enhances Accenture's capabilities, particularly in the State of California, where Highlands Consulting has a strong presence and a proven track record of delivering high-impact strategy and consulting services. Ryan Oakes, global Health & Public Services industry practices chair at Accenture, said: 'Highlands Consulting's strong relationships and credentials with state agencies will help us better serve our clients and unlock new opportunities for reinvention that drives growth and innovation. We are confident that this acquisition will deliver greater outcomes for our clients in the State of California and beyond.' Highlands Consulting, founded in 2002 and headquartered in Sacramento, CA, brings a team of professionals with decades of hands-on experience in strategic business and digital planning, organizational and process change, and IT planning and analysis. The combination of Accenture and Highlands Consulting will offer clients an expanded range of services and a deeper pool of talent to address their most pressing challenges. This move underscores Accenture's commitment to growing its presence and service offerings, leveraging Highlands Consulting's established relationships and credentials with key agencies in California. 'This deal is a natural fit for both organizations. We are joining forces to deliver even more value to our clients,' added Mike Cappelluti, President of Highlands Consulting. 'Accenture's scale and resources will enable us to expand our services and capabilities, while our local expertise and long-standing client relationships will provide a solid foundation for Accenture's growth in the State of California.' Highlands Consulting's knowledge of areas like Health & Human Services, transportation and organizational change management will help Accenture further support long-term growth plans for clients. This acquisition aligns with Accenture's broader strategic goals to enhance service offerings in critical sectors and ensure a smooth transition to deliver immediate value to clients. Financial terms of the transaction were not disclosed. Forward-Looking Statements Except for the historical information and discussions contained herein, statements in this news release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as 'may,' 'will,' 'should,' 'likely,' 'anticipates,' 'aspires,' 'expects,' 'intends,' 'plans,' 'projects,' 'believes,' 'estimates,' 'positioned,' 'outlook,' 'goal,' 'target' and similar expressions are used to identify these forward-looking statements. These statements are not guarantees of future performance nor promises that goals or targets will be met, and involve a number of risks, uncertainties and other factors that are difficult to predict and could cause actual results to differ materially from those expressed or implied. These risks include, without limitation, risks that: the transaction might not achieve the anticipated benefits for Accenture; Accenture's results of operations have been, and may in the future be, adversely affected by volatile, negative or uncertain economic and geopolitical conditions and the effects of these conditions on the company's clients' businesses and levels of business activity; Accenture's business depends on generating and maintaining client demand for the company's services and solutions including through the adaptation and expansion of its services and solutions in response to ongoing changes in technology and offerings, and a significant reduction in such demand or an inability to respond to the evolving technological environment could materially affect the company's results of operations; risks and uncertainties related to the development and use of AI could harm the company's business, damage its reputation or give rise to legal or regulatory action; if Accenture is unable to match people and their skills with client demand around the world and attract and retain professionals with strong leadership skills, the company's business, the utilization rate of the company's professionals and the company's results of operations may be materially adversely affected; Accenture faces legal, reputational and financial risks from any failure to protect client and/or company data from security incidents or cyberattacks; the markets in which Accenture operates are highly competitive, and Accenture might not be able to compete effectively; Accenture's ability to attract and retain business and employees may depend on its reputation in the marketplace; if Accenture does not successfully manage and develop its relationships with key ecosystem partners or fails to anticipate and establish new alliances in new technologies, the company's results of operations could be adversely affected; Accenture's profitability could materially suffer due to pricing pressure, if the company is unable to remain competitive, if its cost-management strategies are unsuccessful or if it experiences delivery inefficiencies or fail to satisfy certain agreed-upon targets or specific service levels; changes in Accenture's level of taxes, as well as audits, investigations and tax proceedings, or changes in tax laws or in their interpretation or enforcement, could have a material adverse effect on the company's effective tax rate, results of operations, cash flows and financial condition; Accenture's results of operations could be materially adversely affected by fluctuations in foreign currency exchange rates; Accenture's debt obligations could adversely affect its business and financial condition; changes to accounting standards or in the estimates and assumptions Accenture makes in connection with the preparation of its consolidated financial statements could adversely affect its financial results; as a result of Accenture's geographically diverse operations and strategy to continue to grow in key markets around the world, the company is more susceptible to certain risks; if Accenture is unable to manage the organizational challenges associated with its size, the company might be unable to achieve its business objectives; Accenture might not be successful at acquiring, investing in or integrating businesses, entering into joint ventures or divesting businesses; Accenture's business could be materially adversely affected if the company incurs legal liability; Accenture's work with government clients exposes the company to additional risks inherent in the government contracting environment; Accenture's global operations expose the company to numerous and sometimes conflicting legal and regulatory requirements; if Accenture is unable to protect or enforce its intellectual property rights or if Accenture's services or solutions infringe upon the intellectual property rights of others or the company loses its ability to utilize the intellectual property of others, its business could be adversely affected; Accenture may be subject to criticism and negative publicity related to its incorporation in Ireland; as well as the risks, uncertainties and other factors discussed under the 'Risk Factors' heading in Accenture plc's most recent Annual Report on Form 10-K, as updated in Item 1A, 'Risk Factors' in its Quarterly Report on Form 10-Q for the second quarter of fiscal 2025, and other documents filed with or furnished to the Securities and Exchange Commission. Statements in this news release speak only as of the date they were made, and Accenture undertakes no duty to update any forward-looking statements made in this news release or to conform such statements to actual results or changes in Accenture's expectations. About Accenture Accenture is a leading global professional services company that helps the world's leading businesses, governments and other organizations build their digital core, optimize their operations, accelerate revenue growth and enhance citizen services—creating tangible value at speed and scale. We are a talent- and innovation-led company with approximately 791,000 people serving clients in more than 120 countries. Technology is at the core of change today, and we are one of the world's leaders in helping drive that change, with strong ecosystem relationships. We combine our strength in technology and leadership in cloud, data and AI with unmatched industry experience, functional expertise and global delivery capability. Our broad range of services, solutions and assets across Strategy & Consulting, Technology, Operations, Industry X and Song, together with our culture of shared success and commitment to creating 360° value, enable us to help our clients reinvent and build trusted, lasting relationships. We measure our success by the 360° value we create for our clients, each other, our shareholders, partners and communities. Visit us at
